Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Percy

Showing results (221-230 of 227) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 227 results.
Cancer Chemotherapy and Pharmacology|April 18, 2022
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancerJulia Manzo, Shannon Puhalla, Shalu Pahuja, et al.
Eclinicalmedicine|January 29, 2025
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trialsJan Rekowski, Christina Guo, Olga Solovyeva, et al.
Eclinicalmedicine|January 29, 2025
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocolsMoreno Ursino, Guillermo Villacampa, Jan Rekowski, et al.
Journal of the National Cancer Institute|April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot StudyBarbara A Conley, Lou Staudt, Naoko Takebe, et al.
The Lancet. Haematology|June 17, 2018
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Frederic Baron, et al.
The Lancet. Haematology|April 28, 2022
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Vishal Bhatnagar, et al.
Cancer Cell|November 20, 2020
Molecular Features of Cancers Exhibiting Exceptional Responses to TreatmentDavid A Wheeler, Naoko Takebe, Toshinori Hinoue, et al.
Pageof 23

Showing results (221-230 of 227) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 227 results.
Cancer Chemotherapy and Pharmacology|April 18, 2022
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancerJulia Manzo, Shannon Puhalla, Shalu Pahuja, et al.
Eclinicalmedicine|January 29, 2025
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trialsJan Rekowski, Christina Guo, Olga Solovyeva, et al.
Eclinicalmedicine|January 29, 2025
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocolsMoreno Ursino, Guillermo Villacampa, Jan Rekowski, et al.
Journal of the National Cancer Institute|April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot StudyBarbara A Conley, Lou Staudt, Naoko Takebe, et al.
The Lancet. Haematology|June 17, 2018
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Frederic Baron, et al.
The Lancet. Haematology|April 28, 2022
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Vishal Bhatnagar, et al.
Cancer Cell|November 20, 2020
Molecular Features of Cancers Exhibiting Exceptional Responses to TreatmentDavid A Wheeler, Naoko Takebe, Toshinori Hinoue, et al.
Pageof 23